Cimzia Injection, Solution
Product Images NDC 50474-710

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Cimzia (NDC 50474-710). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Cimzia 01)

This appears to be a chart showing the percentage of patients in a study sorted by different weeks and treatment groups. The study includes a placebo plus MTX group with 199 patients and a group of 393 patients receiving CIMZIA 200 mg plus MTX. However, without further information, it is difficult to provide a more detailed description.*

FDA Label Image

Figure 2 (Cimzia 02)

This is a table of data showing the response rates to different dosages of a medication called CZP in a group of participants over a span of 24 weeks. The table consists of three groups, with two of them receiving either 200mg CZP every 2 weeks, or 400mg CZP every 4 weeks respectively, while the third group, indicated as the control, received a placebo. The numbers in each group are 136, 138, and 135 respectively, with the response rates indicated in percentages along the Y-axis. The X-axis shows the duration of the study in weeks.*

FDA Label Image

Figure 3 (Cimzia 02a)

The provided text is a comparison table of three different treatments, namely Placebo, CIMZIA 200mg Q2W and CIMZIA 400mg Q4W, administered to a population of 57, 65 and 56 patients respectively. However, the statement "The same patients may not have responded at each time point" indicates that the table is likely part of a larger study analyzing treatment response over time, but without additional information or context, it is difficult to provide a more specific description.*

FDA Label Image

Cimzia 02b

FDA Label Image

Figure A And B (Cimzia 03)

FDA Label Image

Figure C (Cimzia 04)

FDA Label Image

Figure D (Cimzia 05)

FDA Label Image

Figure E (Cimzia 06)

FDA Label Image

Figure F (Cimzia 07)

FDA Label Image

Figure G (Cimzia 08)

FDA Label Image

Figure H (Cimzia 09)

FDA Label Image

Figure I (Cimzia 10)

FDA Label Image

Figure J (Cimzia 11)

FDA Label Image

Figure 1 (Cimzia 12)

FDA Label Image

Figure 2 (Cimzia 13)

FDA Label Image

Figure 3 (Cimzia 14)

FDA Label Image

Figure 4 (Cimzia 15)

FDA Label Image

Figure 5 (Cimzia 16)

FDA Label Image

Figure 6 (Cimzia 17)

FDA Label Image

Principal Display Panel (200 mg/vial carton)

This is a description of a medication with the NDC code 50474-700-62, called Cimziqa. The medication is for subcutaneous use only and contains 200mg/vial of Certolizumab pegol. The contents of the carton must not be separated prior to use. The medication must be reconstituted for 5 seconds. There are 2 injection kits each containing 200mg. The text includes contact information to enroll patients in the Ollicly Nursing program by calling 1-844-UCh Norso (1-844-622-6677). The rest of the text appears to be formatting, disclaimers, and legal information and does not provide any useful information.*

FDA Label Image

Principal Display Panel (200 mg/mL Syringe Carton Box)

This text is a description of the Cimzia starter kit (certolizumab pegol) for subcutaneous injection. It contains 3 cartons of 2 prefilled syringes each, with a concentration of 200 mg/mL. The entire carton should be dispensed as one unit, and a medication guide should be given to each patient. The text also includes a phone number for patient support.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.